Attovia Therapeutics (ATTO) Corporate presentation summary

Strategic vision and platform

• Focus on developing ATTOBODY-based biologics for immune-mediated diseases, targeting large unmet needs in pruritic and inflammatory conditions.

• ATTOBODY platform enables creation of complex, multispecific biologics for difficult-to-drug targets.

• Pipeline includes ATTO-1310 (anti-IL-31), ATTO-2306 (anti-IL-31 x IL-13), and ATTO-1091 (trispecific for IBD), with additional discovery programs underway.

• IPO raised $332.4M, with cash runway projected into 2030.

Lead asset: ATTO-1310 clinical progress

• ATTO-1310 targets IL-31 for rapid, deep itch relief and quarterly dosing potential.

• Phase 1 data show favorable tolerability, low immunogenicity, and sustained IL-31 suppression for at least 12 weeks.

• Demonstrated significant itch relief in chronic pruritus and high-itch atopic dermatitis compared to available competitor data.

• Consistent lesion control and improved quality of life observed in high-itch AD patients.

• Phase 2 trials in CPUO and high-itch AD expected to initiate in 1H 2027.

Pipeline and milestones

• ATTO-2306, a bispecific for inflammatory skin diseases, aims for superior efficacy and convenient dosing versus standard of care.

• ATTO-1091, a trispecific for IBD, targets IL-23, TL1A, and integrin a4β7, with higher potency than benchmarks.

• Multiple programs advancing toward Phase 1 and 2 trials, with key data readouts anticipated from late 2026 through 2027.

• Additional discovery programs (ATTO-006, ATTO-007, ATTO-008) expand cross-indication opportunities.